Show simple item record

dc.contributor.authorHansen, Nen_US
dc.contributor.authorAgerstam, Hen_US
dc.contributor.authorWahlestedt, Men_US
dc.contributor.authorLandberg, Nen_US
dc.contributor.authorAskmyr, Men_US
dc.contributor.authorEhinger, Men_US
dc.contributor.authorRissler, Men_US
dc.contributor.authorLilljebjorn, Hen_US
dc.contributor.authorJohnels, Pen_US
dc.contributor.authorIshiko, Jen_US
dc.contributor.authorMelo, Jen_US
dc.contributor.authorALEXANDER, WARRENen_US
dc.contributor.authorBryder, Den_US
dc.contributor.authorJaras, Men_US
dc.contributor.authorFioretos, Ten_US
dc.date.accessioned2014-05-22T07:53:31Z
dc.date.available2014-05-22T07:53:31Z
dc.date.issued2012en_US
dc.identifier0887-6924en_US
dc.identifier.citationHansen, N., Agerstam, H., Wahlestedt, M., Landberg, N., Askmyr, M., Ehinger, M., et al. (2012). SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. Leukemia, 27(1).en_US
dc.identifier.urihttp://hdl.handle.net/11343/33060
dc.descriptionC1 - Journal Articles Refereed
dc.formatapplication/pdfen_US
dc.subjectHaematology; Cancer and Related Disordersen_US
dc.titleSOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell functionen_US
dc.typeJournal Articleen_US
melbourne.peerreviewPeer Revieweden_US
melbourne.affiliationThe University of Melbourneen_US
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)en_US
melbourne.source.titleLeukemiaen_US
melbourne.source.volume27en_US
melbourne.source.issue1en_US
melbourne.publicationid195727
melbourne.elementsidNA
melbourne.contributor.authorAlexander, Warren
melbourne.fieldofresearch320102 Haematology
melbourne.seocode200199 Clinical health not elsewhere classified
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record